Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase 1A/1B study to assess the safety, tolerability and
pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects
with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a
recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug
treatment combination.